Totus Medicines, was recognized with a Stevie Award for our innovative drug discovery platform. The Stevie Awards are the world's premier business awards, and the International Business Awards are the largest and most prestigious business awards program in the world. The awards recognize and reward companies and individuals for outstanding achievements in all aspects of business.
Totus Medicines' drug discovery platform is based on a comprehensive map of molecular drug interactions across the entire human genome. This platform enables the rapid identification and development of new drugs with the potential to treat a wide range of diseases.
"We are honored to be recognized by the Stevie Awards for our innovative drug discovery platform," said Totus Medicines CEO and founder Dr. Neil Dhawan, Ph.D. "Our platform is a powerful tool that has the potential to revolutionize the way we develop new drugs. We are excited to be using our platform to advance our pipeline of novel therapies for cancer and other serious diseases."
At Totus Medicines we are developing a pipeline of other novel therapies based on our drug discovery platform. We are committed to bringing innovative medicines to market that improve the lives of patients with serious diseases.
One of Totus Medicines' most promising drug candidates is TOS-358, a first-in-class covalent PI3Kα inhibitor. TOS-358 is currently in Phase 1 clinical trials for the treatment of various solid tumors with known PI3Kα mutations. PI3Kα is a protein that plays a critical role in cell growth and survival. Mutations in PI3Kα are common in many types of cancer, and PI3Kα inhibitors have the potential to be highly effective in treating these cancers.